<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03863782</url>
  </required_header>
  <id_info>
    <org_study_id>CRC_GHN_2018_001</org_study_id>
    <nct_id>NCT03863782</nct_id>
  </id_info>
  <brief_title>Lyon Sarcoid Uveitis Cohort</brief_title>
  <acronym>LUCS</acronym>
  <official_title>Lyon Sarcoid Uveitis Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sarcoidosis is a systemic disease with unknown etiology. Chronicity of the disease is
      observed in 1/3 of cases. Five percent of the affected patients are expected to die due to
      pulmonary worsening. After pulmonary complications, ocular complications are one of the most
      frequent complications. In hospital setting 2 to 15% of patients who come for initial uveitis
      diagnosis are after examination due to Sarcoidosis. Sarcoidosis diagnosis is based on
      paraclinical exams (biological, radiography) and histological confirmation. Corticotherapy
      (local or general) is usually used to cure sarcoid uveitis. In case of failure
      immunosuppressor or anti-tumor necrosis factor (TNF) can be used. In 10% of cases ocular
      symptoms including blindness are observed. Only treatment administrated quickly after
      diagnosis of sarcoid uveitis can prevent from ophthalmologic complications.

      The main objective of the Lyon Sarcoid Uveitis Cohort study is to analyze the relevance of
      the paraclinical exam for sarcoid uveitis diagnosis, and to define a better visual and
      extra-ophthalmologic prognosis and describe the therapeutic practice in our Department.

      This study is proposed to all patients diagnosed with Sarcoid uveitis with a histological
      confirmation and referred to the internal medicine department of the Croix-Rousse hospital,
      Lyon, France, for etiologic diagnosis or treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical evolution (persistence or resolution) evaluated by gradation of SEN</measure>
    <time_frame>At one year after diagnosis</time_frame>
    <description>Persistence of disease is characterized by persistence of intraocular inflammation evaluated by gradation of SEN. (reference: A Standardization Grading System for Scleritis . Ophthalmology 2011 Apr;118(4):768-71). SEN score ranges from 0 to 5 (resolution = score 0 and persistence = score &gt;0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anatomic characteristic of sarcoid uveitis</measure>
    <time_frame>At inclusion visit</time_frame>
    <description>The anatomic characteristics of sarcoid uveitis will be described: anterior or posterior inflammation of greater rings of iris, ciliary margin of iris</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticoid treatment duration</measure>
    <time_frame>At one year after diagnosis</time_frame>
    <description>Treatment used to cure uveitis: duration of corticotherapy treatment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sarcoid Uveitis</condition>
  <arm_group>
    <arm_group_label>Sarcoid uveitis</arm_group_label>
    <description>The cohort is composed by patients diagnosed or treated for sarcoid uveitis in the departement for Internal Medicine, Croix Rousse Hospital, Lyon, France.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No specific intervention. Collection of clinical data</description>
    <arm_group_label>Sarcoid uveitis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study is proposed to all patients with a diagnosis of sarcoid uveitis and referred to
        the Internal Medicine department of the Croix-Rousse hospital

        .
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of sarcoid uveitis

          -  First consultation in the department of Internal Medicine at the Croix-Rousse
             hospital, Lyon, France

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pascal SEVE</last_name>
    <email>pascal.seve@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nora Martel</last_name>
    <email>nora.martel@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal SEVE</last_name>
      <email>pascal.seve@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

